The effects of paclitaxel on the three phases of restenosis. Smooth muscle cell proliferation, migration, and matrix formation: An in vitro study

Investigative Radiology

Volumn 39, Issue 9, 2004, Pages 565-571

  Wiskirchen, Jakub ^a   Schöber, Wolfgang ^a   Schart, Nadine ^a   Kehlbach, Rainer ^a   Wersebe, Annika ^a   Tepe, Gunnar ^a   Claussen, Claus D ^a   Duda, Stephan H ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Biologic effects; Paclitaxel; PTA; Restenosis

Indexed keywords

PACLITAXEL; TENASCIN;

ARTERY MUSCLE; ARTICLE; CELL CYCLE G2 PHASE; CELL MIGRATION; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMING UNIT; DRUG EFFECT; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN SECRETION; REGENERATION; RESTENOSIS; SMOOTH MUSCLE FIBER; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 4143123209     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000133815.22434.55     Document Type: Article

References (42)

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation. 1964;30:654-670.
2. Grüntzig A, Hopff H. Perkutane Rekanalisation chronischer arterieller Verschlüsse mit einem neuen Dilatationskatheter. Modifikation der Dotter-Technik. Dtsch Med Wochenschr. 1974;99:2502-2505.
3. Popma JJ, Topol EJ. Factors influencing restenosis after coronary angioplasty. Am J Med. 1990;88:16N-24N.
4. Kuntz RE, Safian RD, Levine MJ, et al. Novel approach to the analysis of restenosis after the use of three new coronary devices. J Am Coll Cardiol. 1992;19:1493-1499.
5. Hanke H, Strohschneider T, Oberhoff M, et al. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res. 1990;67:651-659.
6. Robaina S, Jayachandran B, He Y, et al. Platelet adhesion to stimulated stented surfaces. J Endovasc Ther. 2003;10:978-986.
7. Sullivan TM, Ainsworth SD, Langan EM, et al. Effect of endovascular stent strut geometry on vascular injury, myointimal hyperplasia, and restenosis. J Vasc Surg. 2002;36:143-149.
8. Vernhet H, Jean B, Lust S, et al. Wall mechanics of the stented extracranial carotid artery. Stroke. 2003;34:e222-e224.
9. Albiero R, Nishida T, Adamian M, et al. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation. 2000;101:2454-2457.
10. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart. 2002;87:305-307.
11. Grube E, Silber S, Hauptmann KE, et al. TAXUS I. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003; 107:38-42.
12. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature. 1979;277:665-667.
13. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 1980;77:1561-1565.
14. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35:1969-76.
15. Signore PE, Machan LS, Jackson JK, et al. Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries. J Vasc Interv Radiol. 2001;12:79-88.
16. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-95.
17. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.
18. Suh H, Jeong B, Rathi R, et al. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/ glycolide) nanospheres. J Biomed Mater Res. 1998;42:331-338.
19. Chandy T, Rao GH, Wilson RF, et al. Development of poly(Lactic acid)/chitosan co-matrix microspheres: controlled release of taxol-heparin for preventing restenosis. Drug Deliv. 2001;8:77-86.
20. Das GS, Rao GHR, Wilson RF, et al. Controlled delivery of taxol from poly(ethylene glycol)-coated poly(lactic acid)microspheres. J Biomed Mater Res. 2001;55:96-103.
21. Scheller B, Speck U, Schmitt A, et al. Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting. Invest Radiol. 2002; 37:29-34.
22. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002;106:2649-2651.
23. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104:600-605.
24. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42:1415-1420.
25. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
26. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial. In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559-564.
27. Adamian M, Colombo A, Briguori C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardiol. 2001;38:672-679.
28. Elezi S, Kastrati A, Hadamitzky M, et al. Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis. Catheter Cardiovasc Interv. 1999;48:151-156.
29. Alfonso F, Cequier A, Zueco J, et al. Stenting the stent: initial results and long-term clinical and angiographic outcome of coronary stenting for patients with in-stent restenosis. Am J Cardiol. 2000;85:327-332.
30. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
31. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-645.
32. Kalinowski M, Alfke H, Kleb B, et al. Paclitaxel inhibits proliferation of cell lines responsible for metal stent obstruction: possible topical application in malignant bile duct obstructions. Invest Radiol. 2002;37:399-404.
33. Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation. 2003;107:777-784.
34. Jackson CL, Raines EW, Ross R, et al. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993;13:1218-1226.
35. Fingerle J, Johnson R, Cowes AW, et al. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA. 1989;86:8412-8416.
36. Domnina LV, Ivanova OY, Vasiliev JM. Effect of micotubule-specific drugs upon spatial organization of extracellular matrix in fibroblast cultures. Cell Biol Int. 1995;19:742-748.
37. Terzis AJ, Thorsen F, Heese O, et al. Proliferation, migration, and invasion of human glioma cells exposed to paclitaxel(Taxol) in vitro. Br J Cancer. 1997;75:1744-1752.
38. Berlotti D, Vergani V, Drudis T, et al. The micotubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843-1849.
39. Hotchkiss KA, Ashton AW, Mahmood R, et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther. 2002;1:1191-1200.
40. Hamm-Alvarez SF, Alayof BE, Himmel HM, et al. Coordinate depression of bradykinin receptor recycling and microtubule-dependent transport by Taxol. Proc Natl Acad Sci USA. 1994;91:7812-7816.
41. Liu SM, Magnusson KE, Sundqvist T. Microtubules are involved in transport of macromolecules by vesicles in cultured bovine aortic endothelial cells. J Cell Physiol. 1993;156:311-316.
42. Grigoriev IS, Chernobelskaya AA, Vorobjev IA. Nocodazole, vinblastine and taxol at low concentrations affect fibroblast locomotion and saltatory movements of organelles. Membr Cell Biol. 1999;13:23-48.